GlassScriptPhysician profile
Alexander C Hadley
NPI 1881679215
$8,683.56
in general payments reported to CMS, 2019-2025
42 companies · $1,638 in 2025
The $1,638 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,431 · 2020: $465 · 2021: $526 · 2022: $1,234 · 2023: $1,935 · 2024: $1,455 · 2025: $1,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,889 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,888.87 |
| Education | $139.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $941.52 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Amgen INC. | $776.56 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $693.46 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $558.51 | 2019-2025 | |
| Vifor Pharma, INC. | $517.46 | 2019-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $412.90 | 2020-2025 | Acthar, Terlivaz |
| Alexion Pharmaceuticals, INC. | $371.97 | 2019-2025 | Ultomiris |
| Travere Therapeutics, INC. | $358.15 | 2022-2025 | |
| Akebia Therapeutics INC | $325.20 | 2019-2025 | Vafseo |
| Horizon Therapeutics Plc | $320.44 | 2019-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $308.60 | 2019 | |
| Novo Nordisk INC | $304.89 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $298.48 | 2021-2025 | Benlysta, Jesduvroq |
| Ani Pharmaceuticals, INC. | $274.04 | 2022-2025 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $260.80 | 2021-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Hadley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.